<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02949570</url>
  </required_header>
  <id_info>
    <org_study_id>ICT10</org_study_id>
    <secondary_id>2014-004347-12</secondary_id>
    <nct_id>NCT02949570</nct_id>
  </id_info>
  <brief_title>Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study</brief_title>
  <acronym>ICT10</acronym>
  <official_title>Phase 2 Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hybrigenics Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hybrigenics Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy of inecalcitol in combination with imatinib in CML patients with&#xD;
      molecular residual disease on imatinib monotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine:&#xD;
&#xD;
        -  Duration of response&#xD;
&#xD;
        -  Progression free survival&#xD;
&#xD;
        -  Proportion of responders 2 years after discontinuation of inecalcitol&#xD;
&#xD;
        -  Duration of response after discontinuation of inecalcitol and imatinib&#xD;
&#xD;
        -  Bone remodelling effect&#xD;
&#xD;
        -  Safety of inecalcitol in combination with imatinib&#xD;
&#xD;
        -  Quality of Life&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure the proportion of responders</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of responder defined as patients achieving MR4.5 (i.e. detectable disease ≤ 0.0032 % BCR-ABLIS or undetectable disease with cDNA with ≥32,000 ABL1 transcripts) at any time within 12 months after the initiation of inecalcitol.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>CML, Chronic Phase</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inecalcitol</intervention_name>
    <description>Prospective open label, non-comparative, multicentre exploratory study. Divided in 2 parts Part1: Inecalcitol treatment will be added to imatinib for 12 months. Part 2: Follow-up after discontinuation of inecalcitol. Imatinib will be maintained for 2 years and then will be stopped for those still in MR4.5. These patients will then be followed for 2 additional years after discontinuation of imatinib.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women aged of at least 18 years at the time of informed consent signature;&#xD;
&#xD;
          -  Patients have signed written informed consent;&#xD;
&#xD;
          -  ECOG performance status &lt; 2;&#xD;
&#xD;
          -  Patients with Philadelphia chromosome positive chronic phase CML and M BCR-ABL&#xD;
             transcript positivity (e13a2 or e14a2);&#xD;
&#xD;
          -  Treatment with imatinib for more than 2 years (a history of treatment with interferon&#xD;
             is tolerated);&#xD;
&#xD;
          -  Patient in complete cytogenetic response with BCR-ABL/ABL status between 0.1%&#xD;
             International Scale (IS) and 0.01% IS and no BCR-ABL checkpoint in the last six months&#xD;
             better than Molecular Response MR4 ( i.e. BCR-ABL ratio &lt; 0.01% IS);&#xD;
&#xD;
          -  Women of child bearing potential have a negative pregnancy test prior to first dose&#xD;
             and agree to practice effective contraception during the study;&#xD;
&#xD;
          -  Fertile men agree to practice effective contraception during the study;&#xD;
&#xD;
          -  Patients agree to comply with the study requirements and agree to come to the clinic&#xD;
             for required study visits;&#xD;
&#xD;
          -  Patients agree to follow medication restrictions during the study;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Expression of unusual BCR-ABL transcripts (other than e13a2 or e14a2);&#xD;
&#xD;
          -  Pregnant or lactating women;&#xD;
&#xD;
          -  Participating in another clinical trial with any investigative drug within 30 days&#xD;
             prior to study enrolment(except for OPTIM imatinib);&#xD;
&#xD;
          -  Treatment with interferon within the last 24 months;&#xD;
&#xD;
          -  Imatinib dose modification within the last 3 months;&#xD;
&#xD;
          -  Prior history of haematopoietic stem cell transplantation;&#xD;
&#xD;
          -  Impaired renal function with creatinine clearance &lt; 30 ml/min/1.73m² according to the&#xD;
             MDRD formula;&#xD;
&#xD;
          -  Hypercalcemia (corrected with albuminemia);&#xD;
&#xD;
          -  History of diseases known to be associated with calcium disorders: ongoing&#xD;
             hyperparathyroidism, sarcoidosis….;&#xD;
&#xD;
          -  Presence or history of symptomatic kidney stones in the last 5 years;&#xD;
&#xD;
          -  Current use of drugs known to influence serum calcium (such as thiazide diuretics,&#xD;
             teriparatide, calcitonin and multivitamin supplements containing &gt; 400 IU of vitamin D&#xD;
             or calcium);&#xD;
&#xD;
          -  Current use of digitalis;&#xD;
&#xD;
          -  Current use of drugs which could influence bioavailability of inecalcitol (such as&#xD;
             magnesium-containing antacids, bile-resin binders);&#xD;
&#xD;
          -  Patients with a chronic condition which is not well controlled that, according to the&#xD;
             investigator, would interfere with the completion of the study;&#xD;
&#xD;
          -  Use of any other experimental drug, therapy or vitamin D supplementation within 30&#xD;
             days of first inecalcitol administration;&#xD;
&#xD;
          -  Patients with a mental deficiency preventing proper understanding of trial protocol&#xD;
             requirements;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Francois Dufour-Lamartinie, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hybrigenics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Francois Dufour-Lamartinie, MD</last_name>
    <phone>+33-158103805</phone>
    <email>jfdufour@hybrigenics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyacinthe Johnson- Ansah, MD</last_name>
      <phone>+33-2-31-27-25-39</phone>
      <email>johnsonansah-a@chu-caen.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>October 27, 2016</study_first_submitted>
  <study_first_submitted_qc>October 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2016</study_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

